StreetInsider.com News Articles

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function

Mon, 26 Oct 2026 07:00:00 -0400

Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years
Tumor responses remained robust1 and durable2

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced new two-year follow up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function

Mon, 26 Oct 2026 07:00:00 -0400

Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years
Tumor responses remained robust1 and durable2

Not intended for UK-based media

Merck KGaA to acquire Silence Therapeutics for $1.1B

Mon, 19 Oct 2026 08:00:43 -0400

Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.

The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.

The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy

Merck KGaA to acquire Silence Therapeutics for $1.1B

Mon, 19 Oct 2026 08:00:43 -0400

The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy

Merck KGaA to acquire Silence Therapeutics for $1.1B

Mon, 19 Oct 2026 08:00:43 -0400

The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy

Merck KGaA to acquire Silence Therapeutics for $1.1B

Mon, 19 Oct 2026 08:00:43 -0400

The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy

Merck KGaA to acquire Silence Therapeutics for $1.1B

Mon, 19 Oct 2026 08:00:43 -0400

The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy

Merck KGaA to acquire Silence Therapeutics for $1.1B

Mon, 19 Oct 2026 08:00:43 -0400

The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Mon, 19 Oct 2026 08:00:00 -0400

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion
Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)
Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Mon, 19 Oct 2026 08:00:00 -0400

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion
Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)
Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Mon, 19 Oct 2026 08:00:00 -0400

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion
Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)
Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Mon, 19 Oct 2026 08:00:00 -0400

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion
Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)
Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Mon, 19 Oct 2026 08:00:00 -0400

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion
Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)
Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Mon, 19 Oct 2026 08:00:00 -0400

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion
Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)
Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator

Not intended for UK-based media

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive

MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe